Table 2.
Primary endpoints
| Study group (n=19) | Control group (n=38) | p-value | |
|---|---|---|---|
| Symptomatic hypocalcemia, n (%) | 8 (42%) | 0 | < 0.01 |
| Intravenous calcium replacement, n (%) | 4 (21%) | 0 | < 0.01 |
| LOS (days) | 2.2 ±2.1 | 1.2 ±0.6 | 0.02 |
Primary endpoints
| Study group (n=19) | Control group (n=38) | p-value | |
|---|---|---|---|
| Symptomatic hypocalcemia, n (%) | 8 (42%) | 0 | < 0.01 |
| Intravenous calcium replacement, n (%) | 4 (21%) | 0 | < 0.01 |
| LOS (days) | 2.2 ±2.1 | 1.2 ±0.6 | 0.02 |